Industry News
Biotechnology Industry News
Eli Lilly announced its…
Eli Lilly announced its amylin-Zepbound combination eloraTZP resulted in 23.3% weight loss in adults with type 2 diabetes and obesity or overweight, topping its own triple-G drug candidate retatrutide in that population.
Base editing biotech Beam…
Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets behind one of its lead programs and used them to craft a competing therapy.
Merck & Co. touted a win for…
Merck & Co. touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis suppurativa (HS).
GSK is paying Wave Life Sciences…
GSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’ long-running collaboration.
Connect Biopharma has pointed to…
Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce respiratory attacks—although the study missed a secondary endpoint tied to a breathing test.
Zealand Pharma has shared primary…
Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin analog delivered the highest weight loss—9.8%—at Week 28.
Amgen has shed light on its phase…
Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose.
Eli Lilly has shared detailed data…
Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the top dose of the triple-G drug candidate lost at least 25% of their body
As antiviral specialist Enanta…
As antiviral specialist Enanta Pharmaceuticals endeavors to expand into immunology, the company has decided to lay off 37 employees, Fierce has learned.
Highlight Therapeutics touted…
Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell carcinoma (BCC).
uniQure’s Huntington’s disease…
uniQure’s Huntington’s disease gene therapy has failed to significantly slow disease progression after 48 months, sending the biotech’s stock down 41% when trading began. But mitigating circumstances and the ongoing strength of a secondary endpoint
Novo’s ongoing efforts to…
Novo’s ongoing efforts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.
AstraZeneca is investing $2…
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates (ADCs). The newly minted partners will start by testing ivonescimab with AstraZeneca’s CLDN18.2-directed ADC
ai3Bio has emerged from stealth…
ai3Bio has emerged from stealth with $48 million in funding and a buzzing platform for targeting T cells in autoimmune disease.
Roche has slammed the brakes on an…
Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.
A phase 3 trial of Mirum…
A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s efforts to enter a space recently colonized by Gilead Sciences.
The Biomedical Advanced Research…
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Scynexis a $214 million contract for the development of a treatment for invasive fungal infections.
After vaulting into the clinic by…
After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.
Two of Kodiak Sciences’ drug…
Two of Kodiak Sciences’ drug candidates have matched aflibercept in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.
Merck & Co. has become the…
Merck & Co. has become the latest pharma to jump on the KRAS G12D bandwagon, paying $400 million to China’s SciBrunch for a preclinical candidate.